Alessandra Ferro

620 total citations
37 papers, 315 citations indexed

About

Alessandra Ferro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Alessandra Ferro has authored 37 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Alessandra Ferro's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Alessandra Ferro is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Alessandra Ferro collaborates with scholars based in Italy, Russia and United States. Alessandra Ferro's co-authors include Giulia Pasello, Laura Bonanno, Valentina Guarneri, Pierfranco Conté, Alessandro Dal Maso, Vittorina Zagonel, Fable Zustovich, Patrizia Farina, Alberto Pavan and Giuseppe Aprile and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Alessandra Ferro

35 papers receiving 312 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandra Ferro Italy	11	183	174	79	76	32	37	315
Leonardo Rojas Colombia	10	147 0.8×	151 0.9×	72 0.9×	61 0.8×	18 0.6×	40	268
Giulia Grizzi Italy	12	262 1.4×	185 1.1×	82 1.0×	70 0.9×	30 0.9×	24	370
Patrizia Froesch Switzerland	12	226 1.2×	242 1.4×	66 0.8×	46 0.6×	59 1.8×	31	360
Alessandro Dal Maso Italy	10	286 1.6×	200 1.1×	71 0.9×	99 1.3×	22 0.7×	25	388
Nagla Abdel Karim United States	9	133 0.7×	116 0.7×	53 0.7×	43 0.6×	18 0.6×	33	275
Ilze Bāra United States	9	260 1.4×	225 1.3×	57 0.7×	38 0.5×	22 0.7×	22	365
Ryo Ariyasu Japan	13	273 1.5×	266 1.5×	81 1.0×	104 1.4×	26 0.8×	51	444
Elisa Sottotetti Italy	11	181 1.0×	106 0.6×	101 1.3×	94 1.2×	19 0.6×	21	285
Sergi Clavé Spain	10	207 1.1×	221 1.3×	76 1.0×	117 1.5×	31 1.0×	26	365
Yoshiro Nakahara Japan	12	282 1.5×	255 1.5×	55 0.7×	54 0.7×	12 0.4×	42	414

Countries citing papers authored by Alessandra Ferro

Since Specialization

Citations

This map shows the geographic impact of Alessandra Ferro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandra Ferro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandra Ferro more than expected).

Fields of papers citing papers by Alessandra Ferro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandra Ferro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandra Ferro. The network helps show where Alessandra Ferro may publish in the future.

Co-authorship network of co-authors of Alessandra Ferro

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandra Ferro. A scholar is included among the top collaborators of Alessandra Ferro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandra Ferro. Alessandra Ferro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guerrera, Francesco, Filippo Tommaso Gallina, Eleonora Balzani, et al.. (2025). Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials. Lung Cancer. 209. 108760–108760. 1 indexed citations

Ferro, Alessandra, Michele Bottosso, Maria Vittoria Dieci, et al.. (2024). Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives. Critical Reviews in Oncology/Hematology. 203. 104479–104479. 8 indexed citations

Ferro, Alessandra, et al.. (2024). The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Critical Reviews in Oncology/Hematology. 196. 104295–104295. 29 indexed citations

Pasello, Giulia, Alberto Pavan, M. Nuzzo, et al.. (2024). Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis. Frontiers in Oncology. 14. 3 indexed citations

Marinelli, Daniele, Alessandro Di Federico, Francesca Ambrosi, et al.. (2024). MA01.12 Survival Outcomes and Pathologic Response after Chemo-Immunotherapy in Resectable NSCLC: An Individual Patient Data Meta-Analysis. Journal of Thoracic Oncology. 19(10). S56–S56.

Pasello, Giulia, Alessandro Del Conte, Fabiana Letizia Cecere, et al.. (2024). Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World. The Oncologist. 29(7). 596–608. 2 indexed citations

Maso, Alessandro Dal, et al.. (2024). The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer. Cancer Treatment Reviews. 128. 102768–102768. 10 indexed citations

Bonanno, Laura, et al.. (2024). Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients. Frontiers in Immunology. 15. 1308109–1308109. 10 indexed citations

Pasello, Giulia, Loredana Urso, Ilaria Cavallari, et al.. (2023). 2020P Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1073–S1074. 1 indexed citations

10.

Bonanno, Laura, Davide Massa, M. Nuzzo, et al.. (2023). Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting. The Oncologist. 29(1). e118–e130. 6 indexed citations

11.

Pasello, Giulia, Giorgio Pigato, Loredana Urso, et al.. (2023). 2021P Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1074–S1074. 1 indexed citations

12.

Ferro, Alessandra, Matteo Sepulcri, Marco Schiavon, et al.. (2022). The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. Cancers. 14(22). 5700–5700. 13 indexed citations

13.

Maso, Alessandro Dal, Alessandra Ferro, Sara Pilotto, et al.. (2021). Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology. 17(19). 2513–2527. 8 indexed citations

14.

Pavan, Alberto, Lorenzo Calvetti, Alessandra Ferro, et al.. (2021). Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Translational Lung Cancer Research. 10(1). 202–220. 37 indexed citations

15.

Maso, Alessandro Dal, et al.. (2019). Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology. 138. 87–103. 17 indexed citations

16.

Battaglin, Francesca, Alberto Puccini, Rossana Intini, et al.. (2018). The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy. 18(3). 251–266. 44 indexed citations

17.

Maso, Alessandro Dal, Alessandra Ferro, & Giulia Pasello. (2017). Gender differences in lung cancer. 3(4). 146–149. 4 indexed citations

18.

Zustovich, Fable, Alessandra Ferro, & Patrizia Farina. (2014). Bevacizumab as First-Line Therapy for Patients With Brain Metastases From Renal Carcinoma: A Case Series. Clinical Genitourinary Cancer. 12(3). e107–e110. 5 indexed citations

19.

Zustovich, Fable, Alessandra Ferro, Giuseppe Lombardi, Patrizia Farina, & Vittorina Zagonel. (2014). Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. Chemotherapy. 60(5-6). 294–299. 13 indexed citations

20.

Gambetta, Gregory A., et al.. (2003). [Jeiuno-ileal diverticula complicated by perforation. Clinical case].. PubMed. 58(1). 109–11. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact